Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
4D Molecular Therapeutics
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥50 years of age at time of consent
Treatment naïve MNV secondary to nAMD in the study eye
Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT), in the study eye, at the Screening Visit confirmed by the Reading Center
Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center
BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit
CST less than or equal to 500 microns in the study eye at screening visit, confirmed by the central reading center
You may not be if
Ocular Conditions:
MNV due to causes other than nAMD in either eye (Fibrosis, atrophy, or subretinal hemorrhage in the foveal central subfield (1 mm diameter))
History of retinal detachment in the study eye
History of or presence of active inflammation in either eye
Glaucoma or intraocular hypertension requiring more than 2 topical medications for control
Systemic Conditions and Considerations:
Major illness or major surgical procedure in the 28 days prior to the Screening Visit
Uncontrolled blood pressure
Acute coronary syndrome, myocardial infarction or coronary artery revascularization, cerebrovascular accident, transient ischemic attack within 6 months of the Screening Visit
History of autoimmune condition that may predispose to the development of uveitis
